June 2026 Newsletter: A Selective Reopening of the Biotech IPO Window
- Jun 5
- 4 min read
Dear colleagues, The first three weeks of May produced multiple senior departures at the FDA. The leadership turnover is beginning to shape how companies plan their submissions and how they disclose their risk to investors. For sponsors, the central concern is continuity across FDA interactions. Earlier this year, Replimune and Moderna showed how costly it can be when agency expectations shift after a company has already built around a filing path. This time, the question is more forward-looking: how should sponsors weigh the value of waiting for clearer agency signals against the financing, execution, and competitive costs of delay?
In this issue, we share our read on what the leadership turnover means for sponsors with active programs, examining corporate responses and the broader pattern visible across recent SEC filings. |
Connect with us at BIO. It’s a busy conference season for Headland. Thank you to all our friends, old and new, for connecting with Headland in person at ASCO. If you are attending BIO and want to connect, please reach out using this link or email us at solutions@headlandstrategy.com. |
FDA leadership turnover: Why timing matters. As of mid-May, FDA’s commissioner role and the heads of CDER and CBER were all held by acting officials. Marty Makary resigned as FDA commissioner on May 12, Tracy Beth Høeg was fired from the acting CDER director role later that week, and Katherine Szarama exited the acting CBER role on the same day. Kyle Diamantas, Michael Davis, and Karim Mikhail have stepped into those three positions, respectively, in acting capacities. With Diamantas coming to the commissioner role from the FDA's Human Foods Program, most observers expect his tenure to be transitional. While the senior bench is in flux, companies remain cautious about continuity across agency interactions. Programs that rely on accelerated approval, surrogate endpoints, or nontraditional evidence packages are especially exposed to shifts in evidentiary posture. Advice received at one point in development may carry less value if the next review milestone occurs under different leadership. This makes timing a strategic consideration. A delayed FDA interaction may be valuable if it increases the probability of clear alignment, allows a sponsor to strengthen the evidence package, or reduces the risk of inconsistent feedback. The same delay may be harmful if it weakens investor confidence, shortens runway, slows confirmatory work, or gives competitors more time to advance. When timing becomes strategic: Two responses to the same regulatory uncertainty. On May 14, Regenxbio reported positive topline results from their pivotal Phase 3 Duchenne muscular dystrophy gene therapy program. The company had previously expected to request a pre-BLA meeting in mid-2026, however CMO Steve Pakola told Fierce Biotech that the timing of the next FDA interaction is in flux while the agency's leadership transition settles. In the same interview, Pakola extended the logic to Regenxbio's Hunter syndrome program, delaying the next round of FDA discussions. Under the premise that a mid-2026 FDA interaction would land with an acting CBER director whose authority expires in months, Regenxbio made a directional bet to wait for guidance from a more permanent leader. For a gene therapy relying on “rare disease flexibility,” the risk of being reviewed by one regime and judged by another outweighed the costs of waiting. Across May 10-Q filings, multiple rare disease and gene therapy developers have disclosed the potential risks associated with changes in agency leadership and increased scrutiny of accelerated approval. However, Solid Biosciences, another late-stage gene therapy developer for Duchenne muscular dystrophy, is proceeding with its planned FDA engagements and BLA preparation timeline, showing a different strategy to manage the same uncertainty. Solid Biosciences appears to see value in continued engagement, generating additional feedback to keep their program moving forward to a fileable state. The same category of risk translated into two different strategies. Regenxbio chose to wait for a more settled agency; Solid Biosciences chose to preserve momentum. For sponsors weighing the same tradeoff this quarter, what matters is being able to defend the chosen timing to the board, to investors, and to the next FDA reviewer who picks up the file. Let's talk. If you are facing high-stakes, cross-functional decisions, Headland continues to be a trusted partner to develop and pressure-test commercial, BD/M&A, pipeline, and Medical Affairs strategy. Feel free to reach out to us at solutions@headlandstrategy.com to discuss how we can support your corporate development strategy. This month's newsletter was researched and drafted by Headland Associate Kaitlyn Ryu. |
What we are reading and listening to. A short list of external resources we are finding helpful:
|